The Male Infertility Market, in the next 10 years, is expected to substantiate. Hospital decision support solutions are being floated, and the status quo is expected to stay the same even going forward. Herein, value propositions are made to the society on the whole and patients in particular by the government, private insurance companies, and social security organizations working in unison. As such, the healthcare industry is expected to witness a good number of clinical outcomes in the forthcoming period.
Male fertility is the male’s inability to cause pregnancy in a fertile women. Infertility in men are due to deficiencies in sperm formation, concentration or transportation. Various disorders such as physical problems, psychological problems, hormonal disturbances, causes male infertility. Though many treatment options are available, but somehow in most of the cases treatment don’t work.
In some cases male infertility is caused due to testicular damage leading to inability of testicle to produce sperm. The damaged testicle usually is unable to regain its sperm-making capability and this trait of male infertility is analogous to menopause (though not natural like menopause) which cannot usually be treated. Despite limited ability of medicines to treat male infertility, many successful treatment options are available for many causes.
Some of the factors responsible for growth of male infertility market are changing lifestyle, increasing ages, excess consumption of alcohol and drugs, environmental factors and genetic abnormalities. Moreover, technological advancements are bridging the gap and the spending capacity of individuals has also increased.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/14713
However, demand for male infertility treatment is increasing as there is increasing awareness among the people about their health problems and they are willing to overcoming the social taboo and accepting the fact of male infertility and turning towards the treatment options.
But the high cost of treatment is a major hurdle to most of the people in need for this treatment. Also, the number of repeated treatment failures leads to emotional impact on the patient compelling the patient to opt out of the treatment which is also another limiting factors of male infertility treatment.
Male Infertility Market: Segmentation
|On the basis of symptoms
|On the basis of technique
|On the basis of end-user
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/14713
Approximately 20% of couples attempting for first pregnancy meet with failures. Authorities define these patients as primarily infertile if they have been unable to achieve a pregnancy after one year of unprotected intercourse. Data available over the past decade reveal that around 35% of cases pathology is found in the man alone, and in another 25% both the man and woman are abnormal.
Therefore, the male factor is at least partly responsible in about 50% of infertile couples. According to National Institutes of Health in the U.S. there are approximately 1.5 million infertile couples of which about 35% accounts to male infertility.
There is a steady increase in the global infertility rates both in the developed and developing nations. The changing life style, delayed pregnancy and aging are few of the factors driving the global infertility market in males.
Regionally, the market can be segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America dominates the male infertility market due to factors like, increasing cases of male infertility due to life style factors such as obesity and diet, technological advancements which is fulfilling the need of treatment. Increasing cases of medical tourism and homosexuality in the U.S. is also boosting the male infertility market.
Following North America is Europe owing to encouraging healthcare infrastructure and high healthcare expenditure in this region is the driving factors for male infertility market in this region. Asia Pacific is expected to be a significant market due to the rising infertility cases and awareness about infertility treatments and introduction of newer techniques in the treatment such as DNA fragmentation and computer assisted semen analysis.
Government is also encouraging the adoption of the technological advancements but the private and public insurance plans rarely pay for infertility treatments which limits the lower income people to go for the treatment in this region.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/14713
Some of the major market players of male infertility market include Access Pharmaceuticals, Inc., Andrology Solutions, ASKA Pharmaceutical Co. Ltd, Cordex Pharma, Inc., EMD Serona Inc., Halotech DNA SL, Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, SCSA Diagnostics, and Zydus Cadila Healthcare Limited. Rising incidences of male infertility, increasing healthcare expenditure, development of healthcare infrastructure and urge of having a baby leads to increase in adoption rate of the cutting age treatments leading to rise of the male infertility market.
About Us: Persistence Market Research
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Sales – firstname.lastname@example.org
Website – https://www.persistencemarketresearch.com
Why pay for news and opinions when you can get them for free?
Subscribe for free now!
By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
FINANCE3 days ago
Backpack Raises $17 Million Strategic Series A Round Led by Placeholder VC
NEWS3 days ago
Record year for wind farms raises hope for EU green energy goals
NEWS3 days ago
Russia diamond producer Alrosa’s annual net profit drops 15.2%
NEWS3 days ago
Swisscom in advanced talks to buy Vodafone Italia for $8.7 billion